Reports Q4 revenue $114.3K vs. $312.8K last year. “Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied, with both TFF TAC and TFF VORI demonstrating the potential to significantly improve the product profiles for two FDA-approved therapies,” said Harlan Weisman, M.D., CEO. “As recently announced, we made the decision to prioritize the clinical development of TFF TAC, and we look forward to continuing work on this exciting program, along with evaluating strategic alternatives for the TFF VORI program. We also look forward to our Late-Breaking Abstract Presentation for TFF TAC at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting in mid-April 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- TFF Pharmaceuticals Shares Key Updates with Investors
- TFF Pharmaceuticals to present late-breaking abstract/data at ISHLT 2024
- TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
- TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
